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Introduction {#sec1}
============

Polycomb-group proteins are responsible for the regulation of gene expression by catalyzing repressive histone modifications. They form several types of complexes, including Polycomb repressive complex 2 (PRC2) and PRC1, which are responsible for histone H3 lysine 27 mono-, di-, and tri-methylation (H3K27me1/2/3) and H2AK119 mono-ubiquitination (H2AK119ub1), respectively. PRC2 consists of EED, SUZ12, and the PRC2 enzymatic component, enhancer of zeste homolog 2 (EZH2). PRC2-mediated H3K27me3 plays critical roles in the stage-specific repression of developmental regulator genes, which frequently exhibits bivalency with an active histone modification, H3K4me3, during cellular differentiation. The deregulation of this system has been observed in various types of cancers ([@bib6], [@bib20]).

*EZH1* is another enzymatic component of PRC2 and has a catalytic SET domain showing high homology to that of *EZH2*. The H3K27me2/3 activity of EZH1 is markedly weaker than that of EZH2 *in vivo* ([@bib19]), and, consistent with this finding, no mutation in *EZH1* has been identified, at least in hematological malignancies. The biological importance of EZH1 is considered to be as a backup enzyme for EZH2, which compensates for EZH2 deficiencies in transcriptional repression in embryonic stem (ES) cells, skin stem cells, and hematopoietic cells ([@bib8], [@bib19], [@bib21], [@bib33]). In addition, several groups have revealed that EZH1 forms a non-canonical PRC2 complex that is associated with active transcription ([@bib9], [@bib23], [@bib35], [@bib41]). Another intriguing but controversial issue would be the tissue-specific compensation between EZH1 and EZH2.

PRC2-mediated H3K27me3 cooperates with H2AK119ub1 to repress gene expression. H2AK119ub1 is the epigenetic modification catalyzed by canonical and variant (non-canonical) PRC1s, which contain a RING finger E3 ligase, Ring1B or Ring1A, as the enzymatic component. H2AK119ub1 functions down- and upstream of H3K27me3. In the well-established model, PRC2-induced H3K27me3 recruits canonical PRC1, containing CBX as the H3K27me3-binding module. On the other hand, recent studies have reported the existence of variant PRC1s, which lack CBX proteins but bind to a stretch of unmethylated CpG sites and induce H2AK119ub1, independently of PRC2 ([@bib4], [@bib12], [@bib16]).

Comprehensive genome sequencing studies identified change-of-function mutations in *EZH2*, which increase H3K27me3 levels and reduce H3K27me2 levels, in patients with follicular and diffuse large B-cell lymphomas ([@bib44]). Loss-of-function mutations in *EZH2* have also been identified in patients with myelodysplastic syndrome (MDS) (3%--13%), myeloproliferative neoplasms (MPN) (3%--13%), and MDS/MPN overlap disorders (8%--15.6%), which are all clonal myeloid disorders originating from HSCs ([@bib14], [@bib31]). Since *EZH2* is located at chromosome 7q36.1, chromosomal abnormalities, such as −7 and 7q-, result in deletions of *EZH2* in hematological malignancies ([@bib13]). We demonstrated using mice models that the hematopoietic-cell-specific deletion of *Ezh2* caused a number of hematological malignancies, such as MDS, MDS/MPN, and MPN ([@bib21], [@bib24], [@bib30], [@bib32]). Collectively, these findings suggest a tumor suppressor role for *EZH2* in hematological malignancies. Furthermore, we found that in the absence of *Ezh1*, the loss of *Ezh2* did not induce any hematological malignancies due to the exhaustion of hematopoietic stem cells (HSCs). These findings showed that *Ezh1* plays an essential role in *Ezh2*-insufficient MDS and that at least either Ezh1 or Ezh2 is required for normal HSC maintenance ([@bib21]). The requirement of PRC2 for HSC maintenance has been reported in another mouse model in which *Eed* was deleted in a hematopoietic-cell-specific manner ([@bib40]). *Cdkn2a* was identified as one of the critical target genes (TG) of PRC2 for HSC function because its deletion partially rescued the exhaustion of *Eed*-deleted HSCs, implying the existence of other PRC2 targets involved in HSC maintenance. However, the molecular mechanism underlying *Ezh1*-mediated maintenance of HSCs and MDS stem cells in an *Ezh2*-insufficient setting has not been addressed.

In the present study, we deleted all genes encoding PRC2 enzymatic components, except for a single allele of *Ezh1*, in hematopoietic cells in mice (*Ezh1*^*+/-*^*Ezh2*^*Δ/Δ*^). Using these mice, we revealed that a single allele of *Ezh1* is enough for *Ezh2*-insufficient MDS development. We profiled Ezh1 core TG, which are critical for the maintenance of HSCs as well as MDS stem cells. Furthermore, H2AK119ub1 mediated by PRC1 has been suggested to contribute to the transcriptional repression of Ezh1 core TG in the setting of a PRC2 insufficiency.

Results {#sec2}
=======

*Ezh1*^*+/-*^*Ezh2*^*Δ/Δ*^ Mice Maintain HSC Functions {#sec2.1}
------------------------------------------------------

We previously reported that *Ezh2*^*Δ/Δ*^ mice developed heterogeneous hematological malignancies, mostly MDS and MDS/MPN, whereas *Ezh1*^*−/−*^*Ezh2*^*Δ/Δ*^ (DKO) mice did not develop any disease due to the exhaustion of HSCs ([@bib21]). These findings clearly indicated an important role for *Ezh1* in the maintenance of HSCs and tumor-initiating cells in the setting of an *Ezh2* insufficiency. To clarify the function of *Ezh1* in hematopoiesis and MDS, we generated *Ezh1*^*+/-*^*Ezh2* ^*fl/fl*^ mice to analyze the impact of a one-allele loss of *Ezh1* in *Ezh2*^*Δ/Δ*^ mice. Bone marrow (BM) cells from *Cre-ERT* control, *Cre-ERT*; *Ezh1*^*−/−*^, *Cre-ERT*; *Ezh2*^*fl/fl*^, and *Cre-ERT*; *Ezh1*^*+/-*^*Ezh2*^*fl/fl*^ mice (CD45.2) were transplanted into lethally irradiated CD45.1 recipient mice. *Ezh2* was deleted by intraperitoneal injections of tamoxifen 1 month post-transplantation ([Figure 1](#fig1){ref-type="fig"}A). We hereafter refer to recipient mice reconstituted with *Cre-ERT* control, *Cre-ERT*; *Ezh1*^*−/−*^, *Cre-ERT*; *Ezh2*^*fl/fl*^, and *Cre-ERT*; *Ezh1*^*+/-*^*Ezh2*^*fl/fl*^ cells as wild-type (WT), *Ezh1*^*−/−*^, *Ezh2*^*Δ/Δ*^, and *Ezh1*^*+/-*^*Ezh2*^*Δ/Δ*^ mice, respectively. Genomic PCR and RNA sequencing (RNA-seq) analyses confirmed the efficient deletion of *Ezh2* in *Ezh2*^*Δ/Δ*^ and *Ezh1*^*+/-*^*Ezh2*^*Δ/Δ*^ mice ([Figures 1](#fig1){ref-type="fig"}B and 1C). RNA-seq revealed that *Ezh1* mRNA levels were reduced by approximately 50% in *Ezh1*^*+/-*^*Ezh2*^*Δ/Δ*^ cells ([Figure 1](#fig1){ref-type="fig"}B). A western blot analysis confirmed reductions in the global levels of tri- and di-methylation at histone H3 lysine 27 (H3K27me3 and me2) and the methylation to acetylation switch at H3K27 ([@bib28]) in *Ezh2*^*Δ/Δ*^ and *Ezh1*^*+/-*^*Ezh2*^*Δ/Δ*^ cells. The loss of one *Ezh1* allele had a minimal impact on the global levels of histone modifications at H3K27 ([Figure 1](#fig1){ref-type="fig"}D). Intriguingly, the chimerism of *Ezh1*^*+/-*^*Ezh2*^*Δ/Δ*^ donor cells, like that of WT, *Ezh1*^*−/−*^, and *Ezh2*^*Δ/Δ*^ mice, was almost 100% in peripheral blood (PB) at least for 6 months after *Ezh2* deletion ([Figure 1](#fig1){ref-type="fig"}E). *Ezh1*^*+/-*^*Ezh2*^*Δ/Δ*^ mice showed morphological dysplasia in PB cells ([Figure 1](#fig1){ref-type="fig"}F) as *Ezh2*^*Δ/Δ*^ mice did ([@bib21]), and also showed macrocytic anemia, leukopenia, and increased apoptosis of BM erythroblasts (data not shown). These results indicate that *Ezh1*^*+/-*^*Ezh2*^*Δ/Δ*^ mice developed MDS and maintained MDS stem cells as well as HSCs for a long term.Figure 1Efficient Deletion of *Ezh1* and *Ezh2* in Hematopoietic Cells(A) The experimental scheme of BM transplantation (BMT) and hematopoietic-cell-specific deletion of *Ezh1* and *Ezh2*.(B) Snapshots of RNA-seq signals at *Ezh1* and *Ezh2* gene loci in Lin^−^Sca-I^+^c-Kit^+^ cells (LSK cells) obtained from WT, *Ezh1*^*−/−*^, *Ezh2*^*Δ/Δ*^, and *Ezh1*^*+/-*^*Ezh2*^*Δ/Δ*^ recipient mice 3 months (Mo) after the tamoxifen treatment.(C) Genomic PCR on Lin^-^c-Kit^+^ cells (LK cells) isolated as described in (B), using the tail genomic DNA of donor mice as control.(D) Western blot analysis of global histone modification levels in hematopoietic progenitor cells (HPCs). LK cells isolated as described in (B) were subjected to a western blot analysis using anti-H3K27me3, H3K27me2, H3K27me1, H3K27ac, and histone H3 antibodies.(E) The chimerism of donor-derived CD45.2^+^ cells in the PB of recipient mice.(F) Smear preparation of PB from WT and *Ezh1*^*+/-*^*Ezh2*^*Δ/Δ*^ mice 6 months after the deletion of *Ezh2* observed after May-Giemsa staining. Scale bar, 10 μm.

To further assess the HSC function of *Ezh1*^*+/-*^*Ezh2*^*Δ/Δ*^ HSCs, we first performed competitive repopulating assays ([Figure 2](#fig2){ref-type="fig"}A). BM cells from each genotype were transplanted with a half number of CD45.1^+^ competitor cells. Although the chimerism of *Ezh1*^*+/-*^*Ezh2*^*Δ/Δ*^ donor cells was slightly lower than that of *Ezh2*^*Δ/Δ*^ donor cells in PB, *Ezh1*^*+/-*^*Ezh2*^*Δ/Δ*^ donor cells maintained hematopoiesis for a long term ([Figure 2](#fig2){ref-type="fig"}B). In contrast, DKO donor cells were totally outcompeted by competitor cells. We then performed serial transplantation using WT, *Ezh2*^*Δ/Δ*^, and *Ezh1*^*+/-*^*Ezh2*^*Δ/Δ*^ BM cells without competitor cells ([Figure 2](#fig2){ref-type="fig"}C). Of interest, *Ezh1*^*+/-*^*Ezh2*^*Δ/Δ*^ BM cells did not engraft in 4 of 10 secondary recipients ([Figure 2](#fig2){ref-type="fig"}D) and showed inefficient engraftment in the remaining 6 recipients, although they eventually established high chimerism comparable to that of WT and *Ezh2*^*Δ/Δ*^ cells 6 months after the secondary transplantation ([Figure 2](#fig2){ref-type="fig"}E). A genomic PCR of LK cells obtained 9 months after the secondary transplantation revealed the complete deletion of *Ezh2*, ruling out that incompletely excised *Ezh2* in HSCs contributed to the recovery of chimerism ([Figure 2](#fig2){ref-type="fig"}F). These results indicate that HSC function was attenuated but still maintained in *Ezh1*^*+/-*^*Ezh2*^*Δ/Δ*^ mice.Figure 2*Ezh1*^*+/-*^*Ezh2*^*Δ/Δ*^ Mice Maintain HSC Functions(A) The experimental scheme of competitive repopulating assays. Two million BM cells (CD45.2) from *Cre-ERT*, *Cre-ERT*;*Ezh1*^*−/−*^, *Cre-ERT*;*Ezh2*^*fl/fl*^, and *Cre-ERT*;*Ezh1*^*+/-*^*Ezh2*^*fl/fl*^ were transplanted into lethally irradiated recipient mice (CD45.1) with 1 × 10^6^ competitor BM cells (CD45.1), and *Ezh2* was then deleted by injecting tamoxifen 1 month (Mo) post-transplantation.(B) The chimerism of donor-derived CD45.2^+^ cells in the PB of recipient mice is shown as the ratio of chimerism values before treatment with tamoxifen (left panel). The chimerism 4 months after the tamoxifen treatment is summarized in a bar graph (right panel). Data are shown as the mean ± SD (WT, n = 4; *Ezh1*^*−/−*^, n = 5; *Ezh2*^*Δ/Δ*^, n = 3; *Ezh1*^*+/-*^*Ezh2*^*Δ/Δ*^, n = 4; *Ezh1*^*−/−*^*Ezh2*^*Δ/Δ*^, n = 4).(C) The experimental scheme of serial BM transplantation (BMT). For secondary transplantation, 5 × 10^6^ BM cells from primary recipient mice 3 months after tamoxifen treatment were transplanted into lethally irradiated secondary recipient mice.(D) A summary of the engraftment rates of donor cells in secondary transplantation.(E) The chimerism of donor-derived CD45.2^+^ cells in PB in secondary recipients. Data are shown as the mean ± SD (WT, n = 5; *Ezh2*^*Δ/Δ*^, n = 9; *Ezh1*^*+/-*^*Ezh2*^*Δ/Δ*^, n = 5).(F) Genomic PCR of LK cells obtained from WT, *Ezh2*^*Δ/Δ*^, and *Ezh1*^*+/-*^*Ezh2*^*Δ/Δ*^ recipient mice 9 months after secondary transplantation.\*\*p \< 0.01; and \*\*\*p \< 0.001.

Ezh1 Preferentially Targets Developmental Regulator Genes in *Ezh2*-Insufficient HSPCs {#sec2.2}
--------------------------------------------------------------------------------------

Irrespective of the global loss of H3K27me3, *Ezh1*^*+/-*^*Ezh2*^*Δ/Δ*^ mice maintained HSC function ([Figure 2](#fig2){ref-type="fig"}), whereas DKO mice showed the depletion of HSCs without developing any disease ([Figure 2](#fig2){ref-type="fig"}) ([@bib21]). These results indicate that the residual H3K27me3 marks mediated by only one allele of *Ezh1* in *Ezh1*^*+/-*^*Ezh2*^*Δ/Δ*^ mice maintained repression of critical PRC2 TG in HSCs as well as MDS stem cells. To characterize the genome-wide distribution of residual H3K27me3, chromatin immuniprecipitation (ChIP) sequencing (ChIP-seq)/DNA sequencing was performed on hematopoietic stem and progenitor cells (HSPCs) purified from WT, *Ezh1*^*−/−*^, *Ezh2*^*Δ/Δ*^, and *Ezh1*^*+/-*^*Ezh2*^*Δ/Δ*^ mice. The enrichment of H3K27me3 ChIP signals over input signals at the promoter region (transcription start site \[TSS\] ± 2.0 kb) of each RefSeq gene is shown in scatterplots ([Figure 3](#fig3){ref-type="fig"}A). We defined 5,701 genes with H3K27me3 ChIP signals \>2-fold over input signals at the promoter region (TSS ± 2.0 kb) in WT cells as PRC2 TG ([Figure 3](#fig3){ref-type="fig"}B and [Table S1](#mmc2){ref-type="supplementary-material"}). The *Ezh1* deletion had a limited effect on H3K27me3 levels, whereas the levels were markedly lower in *Ezh2*^*Δ/Δ*^ and *Ezh1*^*+/-*^*Ezh2*^*Δ/Δ*^ cells than in WT cells, as expected from western blot data ([Figure 1](#fig1){ref-type="fig"}D). Only 970 genes were marked with residual H3K27me3 in *Ezh1*^*+/-*^*Ezh2*^*Δ/Δ*^ cells, and we defined them as "Ezh1 core target genes" (Ezh1 core TG) ([Figure 3](#fig3){ref-type="fig"}B and [Table S1](#mmc2){ref-type="supplementary-material"}). H3K27me3 levels at the promoter regions of Ezh1 core TG were significantly higher than those of PRC2 TG ([Figure 3](#fig3){ref-type="fig"}C) and were significantly lower in *Ezh1*^*−/−*^ and *Ezh1*^*+/-*^*Ezh2*^*Δ/Δ*^ cells ([Figure 3](#fig3){ref-type="fig"}C). However, Ezh1 core TG retained high levels of H3K27me3 mark, even in *Ezh1*^*−/−*^ cells ([Figure 3](#fig3){ref-type="fig"}C), suggesting that they are regulated not only by Ezh1 but also by Ezh2. The majority of H3K27me3 genes in *Ezh1*^*+/-*^*Ezh2*^*Δ/Δ*^ cells (Ezh1 core TG) were also included in those in WT, *Ezh1*^*−/−*^, and *Ezh2*^*Δ/Δ*^ cells ([Figure 3](#fig3){ref-type="fig"}D). A heatmap clearly showed that the levels of H3K27me3 around the TSS were profoundly lower in *Ezh2*^*Δ/Δ*^ and *Ezh1*^*+/-*^*Ezh2*^*Δ/Δ*^ cells than in WT and *Ezh1*^*−/−*^ cells ([Figure 3](#fig3){ref-type="fig"}E). These results suggest that in the setting of a PRC2 insufficiency, residual PRC2 is distributed to a restricted number of TG to maintain HSC functions. A gene ontology (GO) analysis showed that Ezh1 core TG were remarkably enriched in genes involved in development, cell differentiation, and transcription ([Figure 4](#fig4){ref-type="fig"}A). A total of 37.7% of the Ezh1 core TG were transcription factors or DNA-binding proteins ([Figure 4](#fig4){ref-type="fig"}B). The expression of Ezh1 core TG was more tightly repressed in the LSK HSPCs of all genotypes than in PRC2 TG ([Figure 4](#fig4){ref-type="fig"}C). Collectively, these results suggest that residual PRC2 preferentially targets developmental regulator genes in *Ezh2*-insufficient HSPCs.Figure 3Profiling of PRC2 Target Genes in *Ezh1*^*+/-*^*Ezh2*^*Δ/Δ*^ HSPCs(A) Scatterplots showing the relationship of the fold enrichment values of H3K27me3 ChIP signals against the input signals (ChIP/input) at TSS ± 2.0 kb of RefSeq genes (listed in RefSeq ID) between WT and *Ezh1*^*−/−*^, *Ezh2*^*Δ/Δ*^, or *Ezh1*^*+/-*^*Ezh2*^*Δ/Δ*^ LK cells 3 months after the tamoxifen treatment.(B) Bar graph showing the number of H3K27me3 genes that showed ≥ 2-fold enrichment in the level of H3K27me3.(C) Box-and-whisker plots showing the H3K27me3 levels of PRC2 target genes (TG) and Ezh1 core TG in the indicated mice. Boxes represent 25--75 percentile ranges. Vertical lines represent 10--90 percentile ranges. Horizontal bars represent medians. Mean values are indicated by red dots.(D) Venn diagram showing the overlap between H3K27me3 genes in *Ezh1*^*+/-*^*Ezh2*^*Δ/Δ*^ LSK cells (Ezh1 core TG) and those in WT, *Ezh1*^*−/−*^, or *Ezh2*^*Δ/Δ*^ LSK cells.(E) Heatmap showing the levels of H3K27me3 at the range of TSS ± 10.0 kb.Figure 4Characterization of Ezh1 Core Target Genes(A) Gene ontology (GO) analysis of Ezh1 core TG using DAVID Bioinformatics Resources.(B) Pie graph showing the breakdown of Ezh1 core TG.(C) Box-and-whisker plots showing the expression levels of PRC2 TG and Ezh1 core TG in LSK cells 3 months (Mo) after the tamoxifen treatment. Boxes represent 25--75 percentile ranges. Vertical lines represent 10--90 percentile ranges. Horizontal bars represent medians. Mean values are indicated by red dots.

Compared with *Ezh2*^*Δ/Δ*^ LSK cells, *Ezh1*^*+/-*^*Ezh2*^*Δ/Δ*^ LSK cells lost H3K27me3 at the promoters of 1,035 genes (designated as *Ezh2*^*Δ/Δ*^/*Ezh1*^*+/-*^*Ezh2*^*Δ/Δ*^ loss genes) ([Table S1](#mmc2){ref-type="supplementary-material"}). A GO analysis showed that these genes were also significantly enriched for developmental regulator genes, despite the much lower levels of enrichment compared with Ezh1core TG ([Figure S1](#mmc1){ref-type="supplementary-material"}A, compared with [Figure 4](#fig4){ref-type="fig"}A). Initial levels of H3K27me3 around TSS were higher than those of PRC2 TG, but lower than those of Ezh1 core TG ([Figure S1](#mmc1){ref-type="supplementary-material"}B). Their expression levels were moderately, albeit not significantly, increased in *Ezh1*^*+/-*^*Ezh2*^*Δ/Δ*^ cells compared with *Ezh2*^*Δ/Δ*^ cells ([Figure S1](#mmc1){ref-type="supplementary-material"}C).

De-repression of Ezh1 Core TG Restricts the Proliferative Capacity of HSCs {#sec2.3}
--------------------------------------------------------------------------

To examine the impact of the complete loss of PRC2 on the expression of Ezh1 core TG, we performed RNA sequence analysis on DKO LSK cells. DKO LSK cells were purified from DKO mice 1 week after the deletion of *Ezh2* due to the immediate depletion of HSCs. The complete deletion of *Ezh1* and *Ezh2* in DKO LSK cells, which was confirmed by RNA sequence data ([Figure S2](#mmc1){ref-type="supplementary-material"}A), induced the de-repression of PRC2 TG, including Ezh1 core TG ([Figure 5](#fig5){ref-type="fig"}A). To identify the PRC2 TG critical for HSC maintenance, we focused on 42 Ezh1 core TG de-repressed in DKO cells relative to *Ezh1*^*+/-*^*Ezh2*^*Δ/Δ*^ cells ([Figure 5](#fig5){ref-type="fig"}B). Among them, *Cdkn2a*, *Cdkn2b*, *Pitx1* ([@bib18]), *Egr2* ([@bib39]), *Egr3* ([@bib5]), *Tbx15* ([@bib42]), and *HtrA1* ([@bib36]) have been reported to negatively regulate cell proliferation or induce cell death. The de-repression of *Cdkn2a*, *Pitx1*, *Egr2*, *Egr3*, *Tbx15*, and *HtrA* in DKO cells was confirmed by a quantitative RT-PCR analysis ([Figure 5](#fig5){ref-type="fig"}C). Manual ChIP assays also confirmed that H3K27me3 levels were significantly reduced at the promoter of *Cdkn2a*, *Pitx1*, and *Egr3* in DKO cells but kept at high levels in *Ezh1*^*+/-*^*Ezh2*^*Δ/Δ*^ cells ([Figure S2](#mmc1){ref-type="supplementary-material"}B). *Cdkn2a* and *Cdkn2b* are representative targets of PRC1 and PRC2 that are critical for the maintenance of the proliferative capacity of HSCs ([@bib10], [@bib25], [@bib27], [@bib40]). To investigate the effects of the de-repression of other Ezh1 core TG in HSCs and MDS stem cells, we transduced LSK cells with *Pitx1*, *Egr2*, *Egr3*, or *Tbx15* lentiviruses. We purified transduced cells expressing Venus as a marker protein of transduction, and then monitored their growth. A quantitative RT-PCR analysis confirmed a significant overexpression of *Pitx1*, *Egr2*, and *Egr3* ([Figure 5](#fig5){ref-type="fig"}D). The overexpression of all the tested genes, particularly *Egr2*, *Egr3*, and *Tbx15*, significantly attenuated the growth of LSK cells under a stem cell culture condition supplemented with Stem cell factor (SCF) and Thrombopoietin (TPO), suggesting that de-repression of each tested gene impairs HSC function ([Figure 5](#fig5){ref-type="fig"}E). De-repression of these Ezh1 core TG might account for the exhaustion of HSCs in DKO mice.Figure 5Identification of Responsible Genes Involved in HSC Depletion in PRC2-Null Mice(A) Box-and-whisker plots showing the expression levels of PRC2 TG and Ezh1 core TG in LSK cells 1 week (wk) after the tamoxifen treatment. Boxes represent 25--75 percentile ranges. Vertical lines represent 10--90 percentile ranges. Horizontal bars represent medians. Mean values are indicated by red dots.(B) Scatterplots showing the relationship between H3K27me3 levels in *Ezh1*^*+/-*^*Ezh2*^*Δ/Δ*^ LSK cells and fold expression levels of PRC2 TG in DKO relative to *Ezh1*^*+/-*^*Ezh2*^*Δ/Δ*^ LSK cells.(C) A quantitative RT-PCR analysis in WT, *Ezh1*^*−/−*^*Ezh2*^*Δ/Δ*^, and DKO LSK cells 1 week after the tamoxifen treatment. mRNA levels were normalized to *Hprt1* expression, and relative expression levels are shown as the mean ± SD of triplicate analyses. Cells with expression levels arbitrarily set to 1 are indicated as "1." ND, not detected.(D and E) Overexpression of selected Ezh1 core TG in WT LSK cells using a lentivirus. Sorted Venus-positive cells were cultured in the presence of SCF and TPO. (D) A quantitative RT-PCR analysis on cells cultured for 10 days. mRNA levels were normalized to *Hprt1* expression, and expression levels relative to the control are shown as the mean ± SD of triplicate analyses. (E) Growth of cells overexpressing the indicated genes. Cell numbers are shown as the mean ± SD of triplicate cultures.\*p \< 0.05; \*\*p \< 0.01; \*\*\*p \< 0.001.

H3K4me3 Was Associated with Ezh1 Core TG {#sec2.4}
----------------------------------------

Bivalent genes marked with a repressive mark H3K27me3 and an active mark H3K4me3 are the so-called developmental regulator genes that are involved in the regulation of development and differentiation ([@bib2], [@bib43]). Given that Ezh1 core TG are rich in developmental regulator genes ([Figure 4](#fig4){ref-type="fig"}A), we profiled H3K4me3 in WT and PRC2-insufficient LSK HSPCs by ChIP-seq analysis ([Figure 6](#fig6){ref-type="fig"}A). Genes with both H3K27me3 and H3K4me3 ChIP signals \>2-fold over input signals at the promoter region (TSS ± 2.0 kb) in WT cells were defined as bivalent genes in LSK cells. We found that 882 of 970 Ezh1 core TG were overlapped with the bivalent genes ([Figure 6](#fig6){ref-type="fig"}B) and were significantly enriched for developmental regulator genes, as evident from the data of GO analysis ([Figure 6](#fig6){ref-type="fig"}C). A heatmap and the following quantitative analysis showed that the levels of H3K4me3 at the promoters of Ezh1 core TG were remarkably higher than those at other PRC2 TG in both WT and *Ezh1*^*+/-*^*Ezh2*^*Δ/Δ*^ cells ([Figures 6](#fig6){ref-type="fig"}D and 6E). Levels of H3K4me3 at the promoters of Ezh1 core TG were slightly reduced in *Ezh1*^*+/-*^*Ezh2*^*Δ/Δ*^ cells but stayed at higher levels than those at other PRC2 TG ([Figures 6](#fig6){ref-type="fig"}A, 6D, and 6E). Taken together, these data suggest that residual PRC2 preferentially targets bivalent developmental regulator genes in its insufficiency.Figure 6Profiling of H3K4me3 in *Ezh1*^*+/-*^*Ezh2*^*Δ/Δ*^ HSPCs(A) Scatterplots showing the relationship of the fold enrichment values (ChIP/input) of H3K27me3 and H3K4me3 at TSS ± 2.0 kb of RefSeq genes. WT, *Ezh1*^*−/−*^, *Ezh2*^*Δ/Δ*^, and *Ezh1*^*+/-*^*Ezh2*^*Δ/Δ*^ LSK cells were obtained from mice 3 months after the tamoxifen treatment. Black and gray dots indicate PRC2 TG and others, respectively.(B) Venn diagram showing the overlap between Ezh1 core TG and bivalent genes in WT LSK cells.(C) GO analysis data of Ezh1 core TG overlapping with bivalent genes in (B) using DAVID Bioinformatics Resources.(D) Heatmap showing H3K27me3 and H3K4me3 levels at the range of TSS ± 10.0 kb.(E) Box-and-whisker plots showing H3K4me3 levels. Boxes represent 25--75 percentile ranges. Vertical lines represent 10--90 percentile ranges. Horizontal bars represent medians. Mean values are indicated by red dots. \*\*\*p \< 0.001.

PRC1-Mediated H2AK119ub1 Was Involved in Repression of Ezh1 Core TG {#sec2.5}
-------------------------------------------------------------------

PRC1 largely shares TG with PRC2 because PRC1-mediated H2AK119ub1 functions up- and downstream of PRC2-mediated H3K27me3 ([@bib3], [@bib4], [@bib7], [@bib15]). We hypothesized that H2AK119ub1 also plays a key role in the repression of PRC2 TG in PRC2-insufficient HSPCs. To test this hypothesis, the state of the H2AK119ub1 modification in *Ezh1*^*+/-*^*Ezh2*^*Δ/Δ*^ LSK HSPCs was examined. For analysis on DKO HSPCs, c-Kit^*+*^ BM cells that were collected 1 week after tamoxifen treatment were used. A western blot analysis showed that the global level of H2AK119ub1 was not significantly changed by the loss of PRC2, even in DKO cells ([Figure 7](#fig7){ref-type="fig"}A). A ChIP-seq analysis of H2AK119ub1 revealed a strong correlation of H2AK119ub1 levels with H3K27me3 levels at the promoters of PRC2 TG, particularly of the Ezh1 core TG in *Ezh1*^*+/-*^*Ezh2*^*Δ/Δ*^ cells ([Figure 7](#fig7){ref-type="fig"}B). The genes, the promoters of which were marked with H3K27me3 and H2AK119ub1, largely overlapped ([Figure 7](#fig7){ref-type="fig"}C). A heatmap and boxplot showed that the deletion of *Ezh1* and/or *Ezh2* had limited effects on the level of H2AK119ub1 at the promoters of PRC2 TG ([Figures 7](#fig7){ref-type="fig"}D and 7E), which is consistent with the global levels of H2AK119ub1 detected in western blots ([Figure 7](#fig7){ref-type="fig"}A). Manual ChIP assays confirmed that H2AK119ub1 levels of selected Ezh1 core TG were maintained at the basal levels in DKO as well as *Ezh1*^*+/-*^*Ezh2*^*Δ/Δ*^ HSPCs ([Figure S2](#mmc1){ref-type="supplementary-material"}C). These results suggest a role for PRC1-mediated H2AK119ub1 in the repression of PRC2 TG in the setting of a PRC2 insufficiency.Figure 7Involvement of H2AK119ub1 in Repression of Ezh1 Core TG(A) Western blot analysis of global histone modification levels in hematopoietic progenitor cells (HPCs). LK cells obtained from mice 3 months (Mo) or c-Kit^+^ cells obtained 1 week (wk) after the tamoxifen treatment were subjected to a western blot analysis using anti-H2AK119ub1 and histone H2A antibodies. H2AK119ub1 amounts relative to total H2A are indicated.(B) Scatterplots showing the relationship of the fold enrichment values (ChIP/input) of H3K27me3 and H2AK119ub1 at TSS ± 2.0 kb of RefSeq genes. WT, *Ezh1*^*−/−*^, *Ezh2*^*Δ/Δ*^, and *Ezh1*^*+/-*^*Ezh2*^*Δ/Δ*^ LSK cells were obtained from mice 3 months after the tamoxifen treatment. Black and gray dots indicate PRC2 TG and others, respectively.(C) Venn diagram showing the overlap between genes marked with H2AK119ub1 and those with H3K27me3 at their promoters in WT (upper) and *Ezh1*^*+/-*^*Ezh2*^*Δ/Δ*^ (lower) LSK cells.(D) Heatmap showing H3K27me3 and H2AK119ub1 levels at the range of TSS ±10.0 kb of PRC2 TG in LSK cells 3 months or c-Kit^*+*^ cells 1 week after the tamoxifen treatment.(E) Box-and-whisker plots showing H3K27me3 and H2AK119ub1 levels of PRC2 TG. Boxes represent 25--75 percentile ranges. Vertical lines represent 10--90 percentile ranges. Horizontal bars represent medians. Mean values are indicated by red dots.

Discussion {#sec3}
==========

Only Ezh2 and its paralog Ezh1 function as H3K27 methyltransferases. No other enzymes have been shown to exhibit similar catalytic activities. We previously reported that the hematopoietic-cell-specific deletion of *Ezh2* did not compromise the self-renewal capacity of HSCs and caused heterogeneous hematological malignancies, including MDS, in mice. In contrast, *Ezh1*^*−/−*^*Ezh2*^*Δ/Δ*^ mice failed to maintain HSCs as well as MDS stem cells ([@bib21]). Here, our ChIP-seq analysis provided a new insight into the epigenetic mechanisms of maintenance of HSCs and MDS stem cells in the setting of an *Ezh2* insufficiency.

Another group also reported the requirement of PRC2 for HSC maintenance using *Eed*-deleted mice, which are similar to *Ezh1*^*−/−*^*Ezh2*^*Δ/Δ*^ (DKO) mice in terms of the complete loss of PRC2 activity ([@bib40]). These findings suggest that Ezh1 plays an important role in the maintenance of HSCs and development of MDS in the setting of an *Ezh2* insufficiency. In the present study, we demonstrated that only one allele of *Ezh1* (*Ezh1*^*+/-*^*Ezh2*^*Δ/Δ*^) was sufficient to maintain HSCs as well as MDS stem cells ([Figure 2](#fig2){ref-type="fig"}), despite the markedly weaker catalytic activity of Ezh1 than Ezh2 ([@bib19]). This result indicates that the minimal levels of H3K27me3 mediated by Ezh1 are sufficient for HSC maintenance.

The enzymatic activity of Ezh1 was previously shown to be markedly weaker than that of Ezh2 *in vitro* and *in vivo* ([@bib19]). Correspondingly, the deletion of *Ezh1* alone (*Ezh1*^*−/−*^) affected H3K27me3 levels in HSPCs much less than that of *Ezh2*. However, in the absence of Ezh2, *Ezh1* heterozygosity had a significant impact on H3K27me3 levels at the promoters of PRC2 TG ([Figures 3](#fig3){ref-type="fig"}A--3C and 3E). Only 970 genes retained H3K27me3 at their promoters in *Ezh1*^*+/-*^*Ezh2*^*Δ/Δ*^ HSPCs ([Figure 3](#fig3){ref-type="fig"}B). These 970 genes, defined as "Ezh1 core TG," were strongly enriched in genes coding for transcription factors and developmental regulators ([Figures 4](#fig4){ref-type="fig"}A and 4B). The forced expression of selected Ezh1 core TG that were de-repressed in DKO HSPCs, including *Pitx1*, *Egr2*, *Egr3*, and *Tbx15*, suppressed the growth of LSK cells *in vitro* ([Figure 5](#fig5){ref-type="fig"}E). Diffuse intrinsic pontine glioma cells with the mutation of H3K27M exhibited attenuated PRC2 function with the global loss of H3K27me3, whereas the H3K27me3 mark was retained by a limited number of genes, including the tumor suppressor gene *CDKN2A*. The inhibition of residual PRC2 activity abolished tumor cell growth following the de-repression of *CDKN2A* ([@bib22]). Collectively, these findings indicate that residual PRC2 preferentially targets critical genes for the maintenance of stem cells in PRC2-insufficient tumor cells. In contrast, 1,035 *Ezh2*^*Δ/Δ*^/*Ezh1*^*+/-*^*Ezh2*^*Δ/Δ*^ loss genes, which lost H3K27me3 at the promoters in *Ezh1*^*+/-*^*Ezh2*^*Δ/Δ*^ LSK cells compared with *Ezh2*^*Δ/Δ*^ LSK cells, also included many developmental regulator genes, and their expression levels were moderately increased in *Ezh1*^*+/-*^*Ezh2*^*Δ/Δ*^ cells compared with *Ezh2*^*Δ/Δ*^ cells ([Figures S1](#mmc1){ref-type="supplementary-material"}A--S1C). Given that the de-repression of developmental regulator genes of Ezh1 core targets affect the function of HSCs, de-repression of *Ezh2*^*Δ/Δ*^/*Ezh1*^*+/-*^*Ezh2*^*Δ/Δ*^ loss genes also could account for the defective function of *Ezh1*^*+/-*^*Ezh2*^*Δ/Δ*^ HSCs/MDS stem cells as observed in [Figure 2](#fig2){ref-type="fig"}.

In addition to H3K27me3, we profiled H3K4me3 in PRC2-insufficient HSPCs ([Figure 6](#fig6){ref-type="fig"}A), since the bivalency of these histone modifications are frequently observed at the promoters of developmental regulator genes ([@bib2], [@bib17], [@bib43]). Consistent with the results of GO analysis ([Figure 4](#fig4){ref-type="fig"}A), Ezh1 core TG were mostly bivalent genes in LSK cells ([Figure 6](#fig6){ref-type="fig"}B). Of note, we detected remarkably higher levels of H3K4me3 at Ezh1 core TG than other PRC2 TG ([Figures 6](#fig6){ref-type="fig"}D and 6E). The high levels of H3K4me3 could serve as a marker for selective targeting of residual PRC2 to Ezh1 core TG.

Many of the developmental regulator genes, such as *Hox* genes, which are well-known targets of PRC2, were included in Ezh1 core TG, but continued to be repressed in PRC2-insufficient LSK cells, even in DKO mice ([Figures 4](#fig4){ref-type="fig"}C, [5](#fig5){ref-type="fig"}A, and 5B). They appeared to be repressed by mechanisms other than PRC2-mediated H3K27me3 in HSPCs. H2AK119ub1 cooperates with H3K27me3 to form a repressive chromatin region called the polycomb domain. In the traditional model, PRC1, which catalyzes H2AK119ub1, is recruited to PRC2-mediated H3K27me3. However, recent studies reported an alternative mechanism, in which PRC1 deposits H2AK119ub1 independently of PRC2. This new type of PRC1 complex has been classified as variant PRC1, whereas PRC1 in the traditional model is called canonical PRC1 ([@bib4]). H2AK119ub1 levels were previously shown to be largely retained in PRC2-deficient mouse ES cells ([@bib38]). Consistent with this finding, we demonstrated that DKO HSPCs exhibited almost the complete retention of H2AK119ub1 at the global level as well as at the promoters of PRC2 TG, suggesting that variant PRC1s, but not canonical PRC1, predominantly contribute to the deposition of H2AK119ub1 in HSPCs as well as in mouse ES cells ([Figures 7](#fig7){ref-type="fig"}A, 7D, and 7E). Since variant PRC1-mediated H2AK119ub1 recruits PRC2, leading to the deposition of H3K27me3 ([@bib3]), variant PRC1-mediated H2AK119ub1 may be one of the mechanisms underlying the preferential targeting of PRC2 to Ezh1 core TG, as well as H3K4me3. In fact, we found that this mark strongly co-localized with H3K27me3 at Ezh1 core TG in *Ezh1*^*+/-*^*Ezh2*^*Δ/Δ*^ HSPCs ([Figure 7](#fig7){ref-type="fig"}B). Intriguingly, inhibition of Ring1A, an enzymatic component of PRC1, has been shown to have an antitumor effect on an MDS cell line and primary CD34^*+*^ cells from patients with MDS ([@bib26]). Therefore, the functional inhibition of PRC1, especially variant PRC1, would represent an interesting approach to eradicate MDS stem cells by inducing the de-repression of Ezh1 core TG in *Ezh2*-insufficient MDS.

Methods {#sec4}
=======

All methods can be found in the accompanying [Transparent Methods supplemental file](#mmc1){ref-type="supplementary-material"}.
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